| Literature DB >> 36233285 |
Hyein Ahn1, Geum Jong Song2, Si-Hyong Jang1, Myoung Won Son2, Hyun Ju Lee1, Moon-Soo Lee2, Ji-Hye Lee1, Mee-Hye Oh1, Geum Cheol Jeong3, Jong Hyuk Yun2, Sang Mi Lee3, Jeong Won Lee4.
Abstract
This study aimed to assess the relationship between the histopathological and textural features of perigastric adipose tissue (AT) on 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) and to evaluate the prognostic significance of perigastric AT textural features in predicting recurrence-free survival (RFS) in patients with gastric cancer. Sixty-nine patients with gastric cancer who underwent staging [18F]FDG PET/CT and subsequent curative surgery were retrospectively reviewed. Textural features of perigastric AT were extracted from PET images. On histopathological analysis, CD4, CD8, and CD163 cell infiltration and matrix metalloproteinase-11 and interleukin-6 (IL-6) expression in perigastric AT were graded. The degree of CD163 cell infiltration in perigastric AT was significantly correlated with the mean standardized uptake value (SUV), SUV histogram entropy, grey-level co-occurrence matrix (GLCM) energy, and GLCM entropy of perigastric AT. The degree of IL-6 expression in the perigastric AT was significantly correlated with the mean and median SUVs of perigastric AT. In multivariate survival analysis, GLCM entropy, GLCM dissimilarity, and GLCM homogeneity of perigastric AT were significant predictors of RFS. The textural features of perigastric AT on [18F]FDG PET/CT significantly correlated with inflammatory response in perigastric AT and were significant prognostic factors for predicting RFS in patients with gastric cancer.Entities:
Keywords: F-18 fluorodeoxyglucose; adipose tissue; positron emission tomography; stomach neoplasm; textural feature
Mesh:
Substances:
Year: 2022 PMID: 36233285 PMCID: PMC9569486 DOI: 10.3390/ijms231911985
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Characteristics of the 69 enrolled patients with gastric cancer.
| Variables | Number of Patients (%) | |
|---|---|---|
| Age (years) | 60 (34–80) * | |
| Sex | Men | 39 (56.5%) |
| Women | 30 (43.5%) | |
| Tumor location | Upper | 7 (10.1%) |
| Middle | 28 (40.6%) | |
| Lower | 34 (49.3%) | |
| Histopathological classification | PAC/TAC | 43 (62.3%) |
| PDAC | 16 (23.2%) | |
| Mucinous carcinoma/SRC | 10 (14.5%) | |
| Lauren classification | Intestinal | 30 (43.5%) |
| Non-intestinal | 39 (56.5%) | |
| pT stage | T1 stage | 9 (13.0%) |
| T2 stage | 17 (24.6%) | |
| T3 stage | 23 (33.3%) | |
| T4 stage | 20 (29.0%) | |
| pN stage | N0 stage | 29 (42.0%) |
| N1−N3 stages | 40 (58.0%) | |
| TNM stage | Stage I | 18 (26.1%) |
| Stage II | 19 (27.5%) | |
| Stage III | 32 (46.4%) | |
| Adjuvant treatment | Yes | 41 (59.4%) |
| No | 28 (40.6%) | |
| CD4 cell infiltration | Grade 0 | 17 (24.6%) |
| Grade 1 | 17 (24.6%) | |
| Grade 2 | 23 (33.3%) | |
| Grade 3 | 12 (17.4%) | |
| CD8 cell infiltration | Grade 0 | 16 (23.2%) |
| Grade 1 | 17 (24.6%) | |
| Grade 2 | 19 (27.5%) | |
| Grade 3 | 17 (24.6%) | |
| CD163 cell infiltration | Grade 0 | 10 (14.5%) |
| Grade 1 | 20 (29.0%) | |
| Grade 2 | 23 (33.3%) | |
| Grade 3 | 16 (23.2%) | |
| MMP-11 expression | Grade 0 | 14 (20.3%) |
| Grade 1 | 22 (31.9%) | |
| Grade 2 | 23 (33.3%) | |
| Grade 3 | 10 (14.5%) | |
| IL-6 expression | Grade 0 | 28 (40.6%) |
| Grade 1 | 24 (34.8%) | |
| Grade 2 | 12 (17.4%) | |
| Grade 3 | 5 (7.2%) | |
* Expressed as a median (range). IL-6, interleukin-6; MMP-11, matrix metalloproteinase-11; PAC, papillary adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; SRC, signet ring cell carcinoma; TAC, well-to-moderately differentiated tubular adenocarcinoma.
Statistical significance of the Kruskal−Wallis test for comparing the maximum SUV of primary tumor and perigastric AT imaging features according to the histopathological results of perigastric AT.
| Variables | CD4 Cell Infiltration | CD8 Cell Infiltration | CD163 Cell Infiltration | MMP-11 Expression | IL-6 Expression |
|---|---|---|---|---|---|
| Maximum SUV of primary tumor | 0.078 | 0.149 | 0.006 | 0.458 | 0.094 |
| First-order PET features of perigastric AT | |||||
| SUV mean | 0.163 | 0.072 | 0.037 | 0.099 | 0.042 |
| SUV std | 0.469 | 0.949 | 0.402 | 0.583 | 0.343 |
| SUV median | 0.189 | 0.062 | 0.095 | 0.122 | 0.025 |
| SUV histogram kurtosis | 0.699 | 0.911 | 0.330 | 0.714 | 0.869 |
| SUV histogram skewness | 0.470 | 0.387 | 0.496 | 0.226 | 0.170 |
| SUV histogram energy | 0.191 | 0.661 | 0.095 | 0.596 | 0.261 |
| SUV histogram entropy | 0.320 | 0.537 | 0.030 | 0.392 | 0.493 |
| Second-order PET features of perigastric AT | |||||
| GLCM contrast | 0.700 | 0.556 | 0.216 | 0.687 | 0.638 |
| GLCM correlation | 0.386 | 0.072 | 0.356 | 0.469 | 0.292 |
| GLCM dissimilarity | 0.648 | 0.622 | 0.097 | 0.721 | 0.830 |
| GLCM energy | 0.122 | 0.145 | 0.023 | 0.752 | 0.066 |
| GLCM entropy | 0.106 | 0.192 | 0.035 | 0.296 | 0.097 |
| GLCM homogeneity | 0.612 | 0.325 | 0.115 | 0.721 | 0.927 |
AT, adipose tissue; GLCM, grey-level co-occurrence matrix; IL-6, interleukin-6; MMP-11, matrix metalloproteinase-11; PET, positron emission tomography; std, standard deviation; SUV, standardized uptake value.
Results of univariate analysis for recurrence-free survival.
| Variables | Hazard Ratio (95% CI) | ||
|---|---|---|---|
| Age (for 1-year increase) | 0.997 | 1.00 (0.97–1.04) | |
| Sex (women vs. men) | 0.295 | 1.63 (0.65–4.10) | |
| Histopathological classification (PAC/TAC vs.) | PDAC | 0.234 | 1.71 (0.71–4.13) |
| Mucinous/SRC | 0.196 | 1.42 (0.86–4.38) | |
| Lauren classification (intestinal vs. non-intestinal) | 0.553 | 1.27 (0.57–2.84) | |
| pT stage (T1–T2 vs. T3–T4) | 0.003 | 20.95 (2.83–155.14) | |
| pN stage (N0 vs. N1–3) | <0.001 | 12.36 (2.90–52.61) | |
| TNM stage | <0.001 | 14.88 (4.41–50.20) | |
| Maximum SUV of primary tumor (for 1.0 increase) | 0.001 | 1.10 (1.04–1.16) | |
| First-order PET features of perigastric AT (for a 0.10 increase) | SUV mean | <0.001 | 1.27 (1.12–1.46) |
| SUV std | 0.464 | 1.17 (0.77–1.75) | |
| SUV median | 0.001 | 1.29 (1.13–1.47) | |
| SUV histogram kurtosis | 0.785 | 1.00 (0.98–1.03) | |
| SUV histogram skewness | 0.157 | 0.94 (0.86–1.02) | |
| SUV histogram energy | 0.017 | 0.61 (0.41–0.91) | |
| SUV histogram entropy | 0.019 | 1.11 (1.02–1.21) | |
| Second-order PET features of perigastric AT (for a 0.10 increase) | GLCM contrast | 0.004 | 1.13 (1.04–1.23) |
| GLCM correlation | 0.087 | 0.82 (0.65–1.03) | |
| GLCM dissimilarity | 0.007 | 1.36 (1.14–1.62) | |
| GLCM energy | 0.022 | 0.58 (0.36–0.92) | |
| GLCM entropy | <0.001 | 1.12 (1.05–1.20) | |
| GLCM homogeneity | 0.003 | 0.40 (0.24–0.65) | |
AT, adipose tissue; CI, confidence interval; GLCM, grey-level co-occurrence matrix; PAC, papillary adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; PET, positron emission tomography; SRC, signet ring cell carcinoma; std, standard deviation; SUV, standardized uptake value; TAC, well-to-moderately differentiated tubular adenocarcinoma.
Results of multivariate analysis of PET textural features for recurrence-free survival after adjustment for age, sex, TNM stage, and the maximum SUV of primary tumor.
| Variables | Hazard Ratio (95% CI) | ||
|---|---|---|---|
| First-order PET features of perigastric AT (for a 0.10 increase) | SUV mean | 0.147 | |
| SUV median | 0.090 | ||
| SUV histogram energy | 0.222 | ||
| SUV histogram entropy | 0.409 | ||
| Second-order PET features of perigastric AT (for 0.10 increase) | GLCM contrast | 0.464 | |
| GLCM dissimilarity | 0.013 | 1.31 (1.06–1.62) | |
| GLCM energy | 0.099 | ||
| GLCM entropy | 0.019 | 1.07 (1.02–1.15) | |
| GLCM homogeneity | 0.012 | 0.42 (0.21–0.82) | |
AT, adipose tissue; CI, confidence interval; GLCM, grey-level co-occurrence matrix; PET, positron emission tomography; SUV, standardized uptake value.
Figure 1Cumulative recurrence-free survival curves based on the GLCM dissimilarity (a), GLCM entropy (b), and GLCM homogeneity (c) of perigastric AT.
Figure 2Maximal intensity projection image (a) and transaxial images (b,c) of [18F]FDG PET/CT illustrating VOI for measuring textural features of perigastric AT. A 59-year-old man underwent [18F]FDG PET/CT for staging work-up of gastric cancer in the stomach body. The gastric cancer lesion showed intensely increased [18F]FDG with the maximum SUV of 17.99 (arrows on (a,b)). A VOI that covers the area within a 1 cm distance to the margin of primary gastric cancer was manually drawn, and perigastric AT was defined as an area of CT-attenuation range between −190 HU and −30 HU within the VOI (red area in (c). The mean SUV, GLCM homogeneity, GLCM entropy, and GLCM dissimilarity of the perigastric AT were 1.05, 0.74, 3.01, and 0.49, respectively. The patient underwent total gastrectomy and was diagnosed with pT2N0 stage moderately differentiated tubular adenocarcinoma. The patient had cancer recurrence 23.9 months after the surgery.
Figure 3Representative images of immunohistochemical analyses of the perigastric AT. Immunohistochemical staining of CD4 (a,f), CD8 (b,g), CD163 (c,h), MMP-11 (d,i), and IL-6 (e,j). Examples of a score range of 0–1 are shown in (a–e), and examples of a score range of 2–3 area shown in (f–j). The magnifications of all images were 200×.
Figure 4Schematic flowchart of the overall workflow.